Takeaways from the Milwaukee HPC User Forum

September 20, 2017Events, Media coverage

Article by Merle Giles, September 19, 2017 A breath of fresh air came from Graham Anthony who spoke about the pursuit of sustainable healthcare through personalized medicine. The Biovista website calls it ‘drug repositioning’ when HPC drives the ability to more effectively and quickly combine patient and general biomedical data to transform medicine. The key … Read More

BioWorld: Biovista lands new backing for AI-driven personalized medicine ‘Prodigy’

August 15, 2017Media coverage

Article By Michael Fitzhug, Staff Writer BioWorld, Monday, August 14, 2017 Drug repositioning specialist Biovista Inc. has tapped Hewlett Packard Enterprise Co. (HPE) to add greater computing power to Project Prodigy, a personalized medicine platform that leverages artificial intelligence (AI) to help doctors identify novel drugs for hard-to-treat patients. HPE, a spin-off of HP Inc. … Read More

Scientists Find New Uses for Old Drugs

December 16, 2013Media coverage

Interview Of Biovista’s President Aris Persidis in Voice Of America by Jessica Berman; Monday, December 10, 2013   Here is an excerpt… “It is a very easy way to explore whether something that is therapeutically beneficial in one area and for one type of patient might be useful for another type of patient,” said Aris … Read More

Repositioning Gains Momentum in Biopharma Partnerships

June 13, 2013Media coverage

Article by Marie Powers in BioWorld; Monday, June 10, 2013 Article summary: Chronic fatigue syndrome (CFS) has been at the center of a vortex of controversy since the FDA handed down a complete response letter on the Toll-like receptor 3 modulator Ampligen (rintatolimod) from Hemispherx Bioscience Inc. – the only drug in development for CFS … Read More

GEN: Seasoned Drugs Offer Therapeutic Gold Mine

May 23, 2013Media coverage

Article by Caitlin Smith GEN: Genetic Engineering & Biotechnology, May 15, 2013 … Biovista has already repositioned two drugs for the progressive form of multiple sclerosis (MS), which has had few treatment options. Most MS drugs, for treatment of the relapsing-remitting form of MS, compromise the patients’ immune systems and have significant side effects. Biovista … Read More